These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28582032)

  • 1. Design Principles of Bioresorbable Polymeric Scaffolds.
    Kossuth MB; Perkins LEL; Rapoza RJ
    Interv Cardiol Clin; 2016 Jul; 5(3):349-355. PubMed ID: 28582032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paving the way to a bioresorbable technology: Development of the absorb BRS program.
    Perkins LE; Kossuth MB; Fox JC; Rapoza RJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):1-9. PubMed ID: 27797462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioresorbable vascular scaffolds in left main coronary artery disease.
    Everaert B; Capranzano P; Tamburino C; Seth A; van Geuns RJ
    EuroIntervention; 2015; 11 Suppl V():V135-8. PubMed ID: 25983148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous coronary intervention: balloons, stents and scaffolds.
    Colleran R; Kastrati A
    Clin Res Cardiol; 2018 Aug; 107(Suppl 2):55-63. PubMed ID: 30039189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro mechanical behavior and in vivo healing response of a novel thin-strut ultrahigh molecular weight poly-l-lactic acid sirolimus-eluting bioresorbable coronary scaffold in normal swine.
    Cheng Y; Gasior P; Ramzipoor K; Lee C; McGregor JC; Conditt GB; McAndrew T; Kaluza GL; Granada JF
    Int J Cardiol; 2019 Jul; 286():21-28. PubMed ID: 30967275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No more metallic cages: an attractive hybrid strategy with bioresorbable vascular scaffold and drug-eluting balloon for diffuse or tandem lesions in the same vessel.
    Naganuma T; Latib A; Ielasi A; Panoulas VF; Sato K; Miyazaki T; Colombo A
    Int J Cardiol; 2014 Apr; 172(3):618-9. PubMed ID: 24495653
    [No Abstract]   [Full Text] [Related]  

  • 8. Design principles and performance of bioresorbable polymeric vascular scaffolds.
    Oberhauser JP; Hossainy S; Rapoza RJ
    EuroIntervention; 2009 Dec; 5 Suppl F():F15-22. PubMed ID: 22100671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioresorbable vascular scaffolds: From patient selection to optimal scaffold implantation; tips and tricks to minimize device failure.
    Tanaka A; Jabbour RJ; Latib A; Colombo A
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):10-20. PubMed ID: 27797460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation.
    Wiebe J; Dörr O; Liebetrau C; Bauer T; Wilkens E; Ilstad H; Boeder N; Elsässer A; Möllmann H; Hamm CW; Nef HM
    Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1144-1151. PubMed ID: 28134094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioresorbable Scaffold With Drug-Coated Balloon: A "Biodegradable" Model for Bifurcation Lesions Treatment. The New Intriguing Chapter of the "Leaving Nothing Behind" Saga.
    Buccheri D; Piraino D; Andolina G
    Am J Cardiol; 2016 Jul; 118(2):308-9. PubMed ID: 27206913
    [No Abstract]   [Full Text] [Related]  

  • 12. Bioresorbable Scaffolds: Clinical Outcomes and Considerations.
    Capodanno D
    Interv Cardiol Clin; 2016 Jul; 5(3):357-363. PubMed ID: 28582033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The unmet needs: How future technologies will address current limitations of bioresorbable scaffold technology.
    Abizaid A; Ribamar Costa J
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):54-59. PubMed ID: 27797459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry.
    Ortega-Paz L; Capodanno D; Giacchi G; Gori T; Nef H; Latib A; Caramanno G; Di Mario C; Naber C; Lesiak M; Capranzano P; Wiebe J; Mehilli J; Araszkiewicz A; Pyxaras S; Mattesini A; Geraci S; Naganuma T; Colombo A; Münzel T; Sabaté M; Tamburino C; Brugaletta S
    Catheter Cardiovasc Interv; 2017 Apr; 89(5):812-818. PubMed ID: 27515568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of acute expansion of bioresorbable vascular scaffolds versus metallic drug-eluting stents in different degrees of calcification: An Optical Coherence Tomography Study.
    Ming Fam J; van Der Sijde JN; Karanasos A; Felix C; Diletti R; van Mieghem N; de Jaegere P; Zijlstra F; Jan van Geuns R; Regar E
    Catheter Cardiovasc Interv; 2017 Apr; 89(5):798-810. PubMed ID: 27717119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current perspectives on the role of bioresorbable scaffolds in the management of coronary artery disease.
    Dziewierz A; Dudek D
    Kardiol Pol; 2018; 76(7):1043-1054. PubMed ID: 30251247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future perspectives on drug-eluting bioresorbable coronary scaffolds.
    Ielasi A; Tespili M
    Future Cardiol; 2014 May; 10(3):409-20. PubMed ID: 24976477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioresorbable vascular scaffold in patients with complex coronary artery disease.
    Tamburino CI; Capranzano P; Longo G; Immè S; Tamburino G; Scalia M; Condorelli A; Francaviglia B; LA Manna A; Sgroi C; Grasso C; DI Salvo ME; Capodanno D; Tamburino C
    Minerva Cardioangiol; 2016 Aug; 64(4):481-6. PubMed ID: 27128353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weighing the potential late benefits versus early hazard associated with bioresorbable vascular scaffolds in percutaneous coronary interventions: a Markov decision analytic model.
    Fazel R; Vilain KA; Cohen DJ; Yeh RW
    Coron Artery Dis; 2020 May; 31(3):230-236. PubMed ID: 31658137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.